Anesthesiology Research Analysis
March 2026 anesthesiology research showcased a shift toward precision, biomarker-guided care and AI-enabled monitoring. A Bayesian, biomarker-enriched phase 3 trial suggested polymyxin B hemoadsorption reduces mortality in endotoxic septic shock, while a validated three-biomarker model refined immunomodulatory decisions in pneumonia/sepsis. Adversarial AI revealed mechanistic biomarkers and neuromodulation targets for disorders of consciousness, and a G protein–biased μ-agonist (oliceridine) hal
Summary
March 2026 anesthesiology research showcased a shift toward precision, biomarker-guided care and AI-enabled monitoring. A Bayesian, biomarker-enriched phase 3 trial suggested polymyxin B hemoadsorption reduces mortality in endotoxic septic shock, while a validated three-biomarker model refined immunomodulatory decisions in pneumonia/sepsis. Adversarial AI revealed mechanistic biomarkers and neuromodulation targets for disorders of consciousness, and a G protein–biased μ-agonist (oliceridine) halved hypoxia during ambulatory gynecologic sedation. Fundamental biology also advanced with Drp1-driven tunneling nanotubes mediating mitochondrial transfer in septic myocardium, opening novel therapeutic avenues.
Selected Articles
1. Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial.
A biomarker-enriched Bayesian phase 3 RCT (n=157) in vasopressor-dependent septic shock with high endotoxin activity showed high posterior probabilities of reduced 28- and 90-day mortality with two sessions of polymyxin B hemoadsorption added to standard care, with acceptable safety.
Impact: Delivers the strongest randomized evidence to date for an endotoxin-targeted extracorporeal therapy in a rigorously phenotyped septic shock subgroup, advancing precision critical care.
Clinical Implications: Consider polymyxin B hemoadsorption as an adjunct in vasopressor-dependent septic shock with endotoxin activity 0.60–0.89 and multiorgan failure, using strict selection, monitoring, and outcome auditing while awaiting larger pragmatic trials.
Key Findings
- Biomarker-enriched enrollment targeted high endotoxin activity (0.60–0.89) in vasopressor-dependent septic shock (n=157).
- 28-day mortality was lower with hemoadsorption (posterior probability of benefit 95.3%; adjusted OR 0.67; 95% CrI 0.39–1.08).
- 90-day posterior probability of benefit was 99.4% (adjusted OR 0.54; 95% CrI 0.32–0.87).
2. Adversarial AI reveals mechanisms and treatments for disorders of consciousness.
A generative adversarial AI trained on >680,000 neuroelectrophysiology samples reproduced cross-species signatures of consciousness vs coma, generated testable mechanistic predictions (e.g., indirect basal ganglia pathway disruption, enhanced inhibitory-to-inhibitory coupling), and highlighted subthalamic nucleus high-frequency stimulation as a candidate intervention.
Impact: Links interpretable AI with causal mechanistic hypotheses and neuromodulation targets, bridging neuroscience, anesthesiology, and critical care to enable targeted trials and refined monitoring.
Clinical Implications: Provides mechanistic biomarkers and a plausible target (subthalamic nucleus stimulation) for prospective neuromodulation studies and informs development of next-generation perioperative consciousness monitors.
Key Findings
- Modeled consciousness vs coma across species using >680,000 10-second electrophysiology samples and validated in 565 human/animal datasets.
- Predicted basal ganglia indirect pathway disruption and increased cortical inhibitory-to-inhibitory coupling, supported by diffusion MRI and RNA-seq/animal data.
- Identified subthalamic nucleus high-frequency stimulation as a promising therapeutic target.
3. Effect of oliceridine on hypoxia during sedated hysteroscopy: a Phase 4 randomized clinical trial.
In a double-blind randomized trial (n=492) of ambulatory gynecologic sedation, oliceridine (a G protein–biased μ-agonist) halved intraoperative hypoxia versus sufentanil, raised nadir SpO2, and reduced supplemental propofol requirements, indicating improved respiratory safety.
Impact: Provides large, pragmatic, blinded evidence that a biased μ-agonist can meaningfully improve respiratory safety during procedural sedation—directly informing opioid selection.
Clinical Implications: Consider oliceridine as an alternative to conventional potent opioids for ambulatory procedural sedation protocols to reduce hypoxia risk, while accounting for availability, monitoring standards, and cost.
Key Findings
- Randomized, double-blind comparison of oliceridine vs sufentanil during sedated hysteroscopy (n=492).
- Intraoperative hypoxia incidence: 9.8% (oliceridine) vs 19.5% (sufentanil); RR 0.50 (95% CI 0.32–0.79; P=0.002).
- Higher nadir SpO2 and reduced supplemental propofol needs with oliceridine.
4. Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial.
A multicohort analysis derived and externally validated a three-biomarker ML framework (procalcitonin, sTREM-1, IL-6) to quantify immune dysregulation (DIP/cDIP), linked to mortality and secondary infection; reanalysis of a hydrocortisone RCT suggested survival benefit confined to severely dysregulated patients.
Impact: Offers a validated, simple, and implementable tool to reduce treatment-effect heterogeneity in sepsis and to guide biomarker-stratified immunomodulation and trial design.
Clinical Implications: Measuring PCT, sTREM-1, and IL-6 can support precision allocation of corticosteroids or other immunomodulators and enable biomarker-stratified trials in pneumonia/sepsis.
Key Findings
- A 3-biomarker model (PCT, sTREM-1, IL-6) achieved high accuracy for immune dysregulation (DIP 91.2%; cDIP RMSE 0.056).
- Higher cDIP independently associated with increased mortality and secondary infections.
- Hydrocortisone RCT reanalysis showed survival benefit only in severe dysregulation (e.g., cDIP ≥0.63).
5. Cytoskeletal remodeling promotes tunneling nanotube formation and drives cardiac resident cell mitochondrial transfer in sepsis.
Using a CLP sepsis model with single-cell transcriptomics, the study shows Drp1-driven cytoskeletal remodeling orchestrates TNT biogenesis and long-range mitochondrial trafficking in cardiac cells; cardiac-specific Drp1 knockout disrupts TNT-mediated exchange and halts metabolic deterioration, nominating Drp1/TNT as a therapeutic axis.
Impact: Reveals a nanoscale organelle-transfer mechanism linking cytoskeletal remodeling to metabolic failure in septic myocardium, opening a tractable molecular target.
Clinical Implications: Targeting Drp1/TNT-mediated mitochondrial exchange could become a novel approach to prevent or mitigate septic cardiomyopathy; requires human tissue validation and pharmacologic modulation studies.
Key Findings
- Drp1-driven cytoskeletal remodeling orchestrates TNT biogenesis enabling mitochondrial trafficking across cardiac cell types.
- Cardiac-specific Drp1 knockout disrupts TNT-mediated mitochondrial exchange and halts metabolic deterioration.
- Single-cell transcriptomics in CLP sepsis mapped TNT-related gene programs and metabolic reprogramming across cardiac cells.